Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000950
Status:
COMPLETED
Last Update Posted:
2011-03-02
First Post:
1999-11-02
Brief Title:
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs isoniazid rifampin ethambutol and pyrazinamide in the blood and the outcome of HIV-positive patients with tuberculosis This study also evaluates how these drugs are absorbed and metabolized in the body
Detailed Description:
Patients receive up to 8 weeks of two or more anti-tuberculosis drugs of which at least two are isoniazid rifampin pyrazinamide or ethambutol Blood specimens are collected at 2 6 and 10 hours after administration of study medication once between Days 10 and 14 of a phase of daily treatment and once while on an intermittent dose regimen twice weekly or three times weekly
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: